Lifecore Biomedical, Inc. Stock Analysis & AI Score
Lifecore Biomedical, Inc. (LFCR) has an ST Score of 37.4 (C), driven by its Forecast (B) and held back by its Growth (D-). Analysts rate it Buy with a $6.50 price target (+51.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Lifecore Biomedical, Inc. (LFCR) has an ST Score of 37.4 (C), driven by its Forecast (B) and held back by its Growth (D-). Analysts rate it Buy with a $6.50 price target (+51.5% upside).
- Strongest
- ForecastB
- Weakest
- GrowthD-
All factor grades
- ForecastB
- ValuationC+
- Financial StrengthC
- ProfitabilityC-
- MomentumD+
- GrowthD-
- Piotroski4/9
Contact
LFCR stock: frequently asked questions
What is LFCR's ST Score?
Lifecore Biomedical, Inc. (LFCR) has an ST Score of 37.4 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is LFCR a buy, hold, or sell?
Analysts rate LFCR a Buy, with a price target of $6.50 (+51.5% vs the current price). Our ST Score grades it C (37.4/100). The ST Score is a data-driven signal, not a recommendation.
What are LFCR's factor grades?
Valuation C+, Profitability C-, Financial Strength C, Momentum D+, Growth D-, Forecast B.
What is LFCR's valuation grade?
Lifecore Biomedical, Inc. (LFCR) earns a valuation grade of C+, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is LFCR's growth grade?
Lifecore Biomedical, Inc. (LFCR) earns a growth grade of D-, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is LFCR's profitability grade?
Lifecore Biomedical, Inc. (LFCR) earns a profitability grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is LFCR's financial strength grade?
Lifecore Biomedical, Inc. (LFCR) earns a financial strength grade of C, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for LFCR?
The average analyst price target for Lifecore Biomedical, Inc. (LFCR) is $6.50 from 7 analysts, which is +51.5% versus the recent price of $4.29.
What is LFCR's Piotroski score?
Lifecore Biomedical, Inc. (LFCR) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.